Henrik Steen Hansen

Medicin og biovidenskab

1. Stents 100%
2. Percutaneous Coronary Intervention 87%
3. Sirolimus 83%
4. ST Elevation Myocardial Infarction 68%
5. Myocardial Infarction 42%
6. Everolimus 37%
7. Polymers 34%
8. Optical Coherence Tomography 33%
9. Coronary Artery Disease 32%
10. Randomized Controlled Trials 27%
11. Non-ST Elevated Myocardial Infarction 25%
12. Drug-Eluting Stents 25%
13. Angina Pectoris 24%
14. 3,5-seco-4-norcholestan-5-one oxime-3-ol 20%
15. Coronary Vessels 19%
16. Infarction 19%
17. Fluspirilene 17%
18. Echocardiography 16%
19. Doppler Echocardiography 16%
20. BES 14%
21. Stroke Volume 13%
22. Acute Coronary Syndrome 13%
23. Ezetimibe 12%
24. Rosuvastatin Calcium 12%
25. Confidence Intervals 12%
26. Lipids 12%
27. Safety 11%
28. Angiography 11%
29. Physical Fitness 10%
30. Therapeutics 10%
31. Antibodies 10%
32. Asthma 10%
33. Reperfusion Injury 10%
34. C-Reactive Protein 10%
35. Hydroxymethylglutaryl-CoA Reductase Inhibitors 9%
36. Placebos 9%
37. Myocardial Ischemia 9%
38. Paclitaxel 9%
39. Magnetic Resonance Spectroscopy 9%
40. Random Allocation 9%
41. Equivalence Trials 8%
42. Left Ventricular Function 8%
43. Population 8%
44. Thrombosis 8%
45. Ischemia 8%
46. Perfusion 8%
47. Stable Angina 8%
48. Diabetes Mellitus 7%
49. Coronary Angiography 7%
50. Coronary Vasospasm 7%